Department of Radiology, Nissay Hospital, 6-3-8 Itachibori, Nishiku, Osaka 550-0012, Japan.
Anticancer Res. 2012 Nov;32(11):5039-44.
To evaluate the initial safety and efficacy of combination therapy using miriplatin plus low-dose epirubicin for transarterial chemoembolisation (TACE) of unresectable hepatocellular carcinoma (HCC).
Patients who underwent TACE using miriplatin plus epirubicin (n=48) and control patients who underwent TACE using miriplatin-alone (n=51) were included in this study.
The objective response rate in the miriplatin plus epirubicin group (91%) was significantly higher than that in the miriplatin group (74%, p=0.024). Concomitant use of miriplatin and epirubicin was an independent factor associated with higher objective response rate (hazard ratio=0.18; p=0.012). Overall incidence adverse events was not significantly different between the miriplatin plus epirubicin group (50%) and the miriplatin group (49%, p=0.575).
TACE using miriplatin plus low-dose epirubicin was associated with an increased objective response rate and comparable adverse effects compared to TACE using miriplatin-alone.
评估米立培南联合低剂量表柔比星经动脉化疗栓塞（TACE）治疗不可切除肝细胞癌（HCC）的初步安全性和有效性。
本研究纳入了接受米立培南联合表柔比星 TACE（n=48）和接受米立培南单药 TACE（n=51）的患者。
米立培南联合表柔比星组的客观缓解率（91%）显著高于米立培南组（74%，p=0.024）。米立培南联合表柔比星的使用是与更高的客观缓解率相关的独立因素（风险比=0.18；p=0.012）。米立培南联合表柔比星组（50%）与米立培南组（49%）的总不良反应发生率无显著差异（p=0.575）。
与米立培南单药 TACE 相比，米立培南联合低剂量表柔比星 TACE 可提高客观缓解率，且不良反应相当。
